利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN104761634A 一种肺癌诊断标志物、抗体及其应用 失效 - 权利终止

  • 专利标题： 一种肺癌诊断标志物、抗体及其应用
  • 专利标题（英）： Lung cancer diagnostic marker, antibody and application thereof
  • 申请号： CN201510142768.7
    申请日： 2015-03-27
  • 公开(公告)号： CN104761634A
    公开(公告)日： 2015-07-08
  • 发明人: 李翀
  • 申请人： 李翀
  • 申请人地址： 北京市朝阳区大屯路15号1617室
  • 专利权人： 李翀
  • 当前专利权人： 李翀
  • 当前专利权人地址： 北京市朝阳区大屯路15号1617室
  • 代理机构： 北京金智普华知识产权代理有限公司
  • 代理商 巴晓艳
  • 生物保藏信息： CGMCC NO.10414 2015.03.25
  • 主分类号： C07K14/705
  • IPC分类号： C07K14/705 ;  C07K16/30 ;  G01N33/577 ;  G01N33/574 ;  C12N5/20
一种肺癌诊断标志物、抗体及其应用
摘要：
本发明利用肺癌细胞免疫动物制备了可以特异性识别肺癌组织的特异性单克隆抗体LC128，所述的抗体的保藏号为CGMCC NO.10414，所述的抗体与肺癌组织以及肺癌细胞系呈强阳性反应，与正常组织以及其他非肺癌细胞无交叉反应。通过LC128单抗与肺癌细胞系特异性结合后鉴定细胞系表达的抗原为N3G4，其为异常糖基化修饰整合素β1，其表位为Neu5Acα2-6GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1，利用LC128结合免疫磁珠法检测临床样本发现，阳性检出率为86.13%，明显高于常规脱落细胞图片的阳性检出率，说明N3G4是一个良好的肺癌标志物，LC128是一种良好的肺癌诊断试剂。
摘要（英）：

The invention relates to a specific monoclonal antibody LC128 capable of specifically identifying a lung cancer tissue by utilizing a lung cancer cell immunity animal. The preservation number of the antibody is CGMCC NO.10414; the antibody is reacted with the lung cancer tissue and a lung cancer cell line strong positively; the antibody is not subjected to cross reaction with a normal tissue or other non-lung cancer cells. By means of specific binding of the LC 128 monoclonal antibody and the lung cancer cell line, an antigen expressed by the cell line is N3G4; the antigen is abnormal glycosylation modified integrin beta1; the epitope is Neu5Ac alpha2-6GlcNAcbeta1-3Ga1beta1-3GlcNAcbeta1-3Ga1beta1; found from detection of a clinical sample by utilizing the LC128 in combination with an immunomagnetic bead method, the positive detection rate is 86.13%; the positive detection rate is obviously higher than that of a conventional exfoliated cell picture; and the fact shows that the N3G4 is a good lung cancer marker and the LC128 is a good lung cancer diagnostic reagent.

公开/授权文献
0/0